We speculate that when CD81 is combined with a specific marker of AMKL tumor cells, such as CD41 or CD61, as a target of a therapy such as CAR-T, it may be possible to specifically eliminate AMKL tumor cells. This evidence concerns the gene ITGA2B and neoplasm.